HK StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

ALEBUND-B

23.220

-0.360-1.53%

Volume:171.50K

Turnover:3.94M

Market Cap:8.08B

PE:-7.56

High:23.500

Open:23.500

Low:22.680

Close:23.580

52wk High:46.820

52wk Low:22.480

Shares:348.00M

HK Float Shares:236.00M

Volume Ratio:2.95

T/O Rate:0.07%

Dividend:- -

Dividend Rate:- -

EPS(LYR):-3.071

ROE:--

ROA:-33.01%

PB:4.91

PE(LYR):-7.56

PS:56.40

Loading ...

Overview Company News Filings

Concept

no data

No relevant data is available

Capital Flow

Inflow:

Outflow:

News

Alebund Pharmaceuticals (Jiangsu) Says IND Application for AP308 Cleared by U.S. FDA

ALEBUND-B Wins US FDA Nod to Start Trial of Novel IgA Nephropathy Drug AP308

Alebund Pharmaceuticals (Jiangsu) - AP308 Clinical Trial Planned Soon Following FDA Ind Clearance

THOMSON REUTERS

Alebund Pharma Wins US FDA Clearance to Start AP308 IgA Nephropathy Trial

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Easy breezy. No more feesies.","description":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","keywords":"Tiger Brokers,U.S. stock trading,Hong Kong stock trading,trading U.S. stocks,stock information,stock prices,U.S. stock quotes,U.S. stock trading,Hong Kong stock trading,IPO trading,buying U.S. stocks,global investment","social":{"ogDescription":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.thetigerbrokers.com/stock/09637"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"NZL","license":"TBKIWI","edition":"fundamental","symbol":"09637","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"09637\",,,,,undefined,":{"symbol":"09637","market":"HK","secType":"STK","nameCN":"ALEBUND-B","latestPrice":23.22,"timestamp":1789523129561,"preClose":23.58,"halted":0,"volume":171500,"delay":0,"changeRate":-0.01526717557251906,"floatShares":236000000,"shares":348000000,"eps":-3.071284,"marketStatus":"Trading","change":-0.36,"latestTime":"09-16 09:45:38","open":23.5,"high":23.5,"low":22.68,"amount":3939722,"amplitude":0.034775,"askPrice":23.3,"askSize":2200,"bidPrice":23.16,"bidSize":400,"shortable":0,"etf":0,"ttmEps":-2.326,"tradingStatus":2,"nextMarketStatus":{"tag":"Noon Closed","tradingStatus":4,"beginTime":1789531200000},"marketStatusCode":2,"adr":0,"listingDate":1782662400000,"exchange":"SEHK","adjPreClose":23.58,"openAndCloseTimeList":[[1789522200000,1789531200000],[1789534800000,1789545600000]],"volumeRatio":2.947794,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"09637\",,,,,undefined,":{"symbol":"09637","floatShares":236000000,"roa":"-33.01%","roe":"--","lyrEps":-3.071284,"volumeRatio":2.947794,"shares":348000000,"dividePrice":0,"high":23.5,"amplitude":0.034775,"preClose":23.58,"low":22.68,"week52Low":22.48,"pbRate":"4.91","psRate":"56.40","week52High":46.82,"institutionHeld":0,"latestPrice":23.22,"committee":-0.692308,"eps":-3.071284,"divideRate":0,"volume":171500,"delay":0,"ttmEps":-2.326,"open":23.5,"prevYearClose":22.6,"prevWeekClose":24.02,"prevMonthClose":31.48,"prevQuarterClose":45.92,"fiveDayClose":25.74,"twentyDayClose":33.18,"sixtyDayClose":22.6},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/09637\",params:#limit:5,,,undefined,":[{"date":"2026-08-26","symbol":"09637","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1787707800000,"name":null,"time":"","dateTimestamp":1787673600000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"09637\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"09637\",market:\"HK\",delay:false,,,undefined,":{"strongBuy":1,"buy":0,"hold":0,"sell":0,"strongSell":0,"meanLabel":"STRONG BUY","meanPercent":1,"analysts":3,"updateTime":1787846400000},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/09637\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"09637","date":"2026-09-15","current":-9.982803,"percent":0.927273,"low":-18.066068,"twenty":-12.952569,"median":-11.644749,"eighty":-10.642718,"high":-8.42626,"avg":-11.859709,"sd":1.761806,"marketCap":8013715606},"quantilePoints":[{"date":"2026-06-26","current":-8.87585,"twenty":-8.87585,"median":-8.87585,"eighty":-8.87585,"marketCap":7680660420},{"date":"2026-07-03","current":-11.883178,"twenty":-18.03155,"median":-11.883178,"eighty":-9.78101,"marketCap":10290725554},{"date":"2026-07-10","current":-12.164969,"twenty":-13.966639,"median":-11.847257,"eighty":-11.12129,"marketCap":10521825071},{"date":"2026-07-17","current":-10.947234,"twenty":-12.322489,"median":-11.455859,"eighty":-10.783874,"marketCap":9502268378},{"date":"2026-07-24","current":-11.320561,"twenty":-11.939536,"median":-11.377389,"eighty":-10.939493,"marketCap":9828526520},{"date":"2026-07-31","current":-10.642718,"twenty":-11.840073,"median":-11.194259,"eighty":-10.78337,"marketCap":9257574772},{"date":"2026-08-07","current":-12.743391,"twenty":-12.396338,"median":-11.399787,"eighty":-10.889159,"marketCap":11106370909},{"date":"2026-08-14","current":-13.03884,"twenty":-12.987078,"median":-11.462395,"eighty":-10.903987,"marketCap":11378252693},{"date":"2026-08-21","current":-12.870195,"twenty":-13.077865,"median":-11.725167,"eighty":-10.931752,"marketCap":11255905890},{"date":"2026-08-28","current":-12.144658,"twenty":-13.077865,"median":-11.990608,"eighty":-10.959851,"marketCap":10623780741},{"date":"2026-09-04","current":-11.919154,"twenty":-12.988947,"median":-11.883178,"eighty":-10.931752,"marketCap":9787744252},{"date":"2026-09-11","current":-9.927508,"twenty":-12.953815,"median":-11.760082,"eighty":-10.889159,"marketCap":8163250588},{"date":"2026-09-15","current":-9.747242,"twenty":-12.952569,"median":-11.644749,"eighty":-10.642718,"marketCap":8013715606}],"updateTime":1789523138244},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"09637\",pageSize:4,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2665431379","title":"Alebund Pharmaceuticals (Jiangsu) Says IND Application for AP308 Cleared by U.S. FDA","url":"https://stock-news.laohu8.com/highlight/detail?id=2665431379","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665431379?lang=en_us&edition=fundamental","pubTime":"2026-09-08 23:31","pubTimestamp":1788881494,"startTime":"0","endTime":"0","summary":"Sept 8 (Reuters) - Alebund Pharmaceuticals (Jiangsu) Ltd <9637.HK>::*INVESTIGATIONAL NEW DRUG APPLICATION FOR AP308 FOR TREATMENT OF IGA NEPHROPATHY CLEARED BY U.S. FDA*Further company coverage: 9637.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260908:nRSDYgyKG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","09637"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1141807270","title":"ALEBUND-B Wins US FDA Nod to Start Trial of Novel IgA Nephropathy Drug AP308","url":"https://stock-news.laohu8.com/highlight/detail?id=1141807270","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1141807270?lang=en_us&edition=fundamental","pubTime":"2026-09-08 20:06","pubTimestamp":1788869176,"startTime":"0","endTime":"0","summary":"ALEBUND-B (09637) has announced that the U.S. Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application for AP308, a first-in-class engineered recombinant IgA...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IBBQ","09939","BK1161","BK1191","BK1574","09637","BK1515","MDTX","IBBJ","PSYK","BMED","159151","159938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665416320","title":"Alebund Pharmaceuticals (Jiangsu) - AP308 Clinical Trial Planned Soon Following FDA Ind Clearance","url":"https://stock-news.laohu8.com/highlight/detail?id=2665416320","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665416320?lang=en_us&edition=fundamental","pubTime":"2026-09-08 20:05","pubTimestamp":1788869101,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260908:nTUA2NDWZM:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["09637","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665132055","title":"Alebund Pharma Wins US FDA Clearance to Start AP308 IgA Nephropathy Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2665132055","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665132055?lang=en_us&edition=fundamental","pubTime":"2026-09-08 20:01","pubTimestamp":1788868895,"startTime":"0","endTime":"0","summary":"Alebund Pharma wins US FDA clearance to start AP308 IgA nephropathy trialAlebund Pharmaceuticals (Jiangsu) secured FDA clearance for an IND for AP308 in IgA nephropathy.Approval enables the start of a","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260908:nNDL3brvHr:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09637","BK1191"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":4,"totalPage":17,"pageCount":1,"totalSize":67,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/09637\",params:#limit:6,delay:false,,,undefined,":[]}}